Lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplantation.

Background: Bronchiolitis obliterans is the most important long-term sequelae of lung transplantation limiting survival. Optimized immunosuppression, including inhalation of cyclosporine A (CsA), may be a promising approach to overcome this problem.

Methods: In this study a liposomal CsA solution was characterized in vitro, doses of 10 and 20 mg were inhaled with the PARI eFlow inhaler by 12 stable lung transplant recipients, and lung deposition was evaluated by gamma scintigraphy.

[Tolerance and contrast density in intravenous cholangiography and cholecystography using a new contrast medium (author's transl)].

The tolerance and diagnostic usefulness of the new intravenous bile contrast medium Endomirabil were subjected to clinical radiological testing. Endomirabil is well tolerated. It is our impression that it has a lower side effect quota than the other contrast media used so far.